|Bid||52.00 x 0|
|Ask||54.00 x 0|
|Day's Range||51.00 - 54.25|
|52 Week Range||19.00 - 79.85|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||220.00|
Shareholders in Diurnal Group plc (LON:DNL) may be thrilled to learn that the analysts have just delivered a major...
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has acquired U.S. marketing rights to Alkindi® Sprinkle from Diurnal Group plc (DNL.L). Alkindi Sprinkle’s New Drug Application (NDA) is currently under review with the U.S Food and Drug Administration (FDA) for approval as a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age.